- Study: Participation in diabetes education associated with greater ability to self-manage
- Study pinpoints protective genetic mutations for Type 2 diabetes
- Teva launches generic drug for cystic fibrosis patients
- Research Now launches diabetes panel
- Appropriations bill to boost funding for Lupus Research Institute's education program
NEW YORK — Israeli drug maker Teva Pharmaceutical Industries is developing a protein that could offer a new way to treat Type 1 diabetes, according to published reports.
Type 1 diabetes is an autoimmune disorder in which the immune system attacks the pancreas's beta cells, but the drug, DiaPep277, stops that from happening, according to Bloomberg.
French drug maker Sanofi originally developed the drug but later gave up on it. Teva, which is developing the drug with Andromeda Biotech, has conducted a phase-3 trial of 457 patients and is planning to start a second one with 450, Bloomberg reported.